Eli Lilly acquires Centessa for up to $7.8bn to enter narcolepsy market

Upfront cash of $38 per share values Centessa at $6.3bn; a $9-per-share CVR tied to FDA approvals adds up to $1.5bn more

$LLY ↗$CNTA ↗

Earnings Season

Share

Eli Lilly acquires Centessa for up to $7.8bn to enter narcolepsy market

In Brief

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal worth up to $7.8 billion, gaining a portfolio of orexin receptor 2 agonists designed to treat narcolepsy and related sleep-wake disorders. The upfront cash consideration of $38 per share represents a 40.5% premium to Centessa's 30-day volume-weighted average price. Centessa's lead candidate, cleminorexton, has shown a potential best-in-class profile in Phase 2a trials across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. The deal is expected to close in the third quarter, pending Centessa shareholder approval, High Court sanction, and regulatory clearance.

Why it matters

Lilly's entry into orexin biology creates direct competitive pressure on Jazz Pharmaceuticals, which holds the incumbent narcolepsy franchise with Xyrem and Xywav. A well-capitalized Lilly commercial launch behind cleminorexton compresses Jazz's pricing power and patient retention in a disease with limited treatment alternatives. Jazz has no orexin-class asset in late-stage development, leaving it structurally exposed if cleminorexton achieves best-in-class wakefulness data.

Lilly Bets $7.8bn on Orexin Biology to Build Sleep Medicine Franchise

Eli Lilly has agreed to buy Centessa Pharmaceuticals for up to $7.8 billion, marking its entry into the fast-developing market for orexin-based treatments for sleep-wake disorders.

Under the terms announced on 31 March, Lilly will pay $38 per share in cash at closing, implying an upfront equity value of approximately $6.3 billion. Centessa shareholders will also receive one non-transferable contingent value right per share, worth up to $9.00 in aggregate, contingent on three FDA approval milestones: $2.00 upon approval of cleminorexton or ORX142 for narcolepsy type 2; $5.00 upon approval for idiopathic hypersomnia; and $2.00 upon any first U.S. FDA approval of either asset, all within defined time windows ending no later than 1 January 2030. The upfront cash represents a premium of 40.5% to Centessa's 30-day volume-weighted average trading price through 30 March 2026.

The strategic rationale centres on orexin receptor 2 biology, which governs the neurological switch controlling wakefulness. Centessa's lead asset, cleminorexton, formerly designated ORX750, has completed Phase 2a studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, with Lilly describing its profile as potentially best-in-class. The pipeline also includes ORX142 and additional preclinical-stage assets with potential application in neurodegenerative and neuropsychiatric conditions.

Carole Ho, executive vice president and president of Lilly Neuroscience, said orexin receptor biology represents a direct intervention on the master mechanism of the sleep-wake cycle and that combining Centessa's portfolio with Lilly's clinical, regulatory, and commercial infrastructure would allow development to proceed at greater speed and scale.

Shareholders representing approximately 24.1% of Centessa's outstanding ordinary shares, including entities affiliated with Medicxi Ventures, Index Ventures, and General Atlantic, have signed voting and support agreements committing to vote in favour of the transaction.

The deal will be implemented via a scheme of arrangement under English and Welsh law and is expected to close in the third quarter of 2026. Conditions include approval by Centessa shareholders, sanction by the High Court of Justice of England and Wales, and customary regulatory clearances.

Morgan Stanley is acting as exclusive financial adviser to Lilly, with Kirkland and Ellis as legal counsel. Centessa is advised by Centerview Partners and Jefferies, with Goodwin Procter as legal counsel.

Narcolepsy affects an estimated three million people globally, and Centessa is one of several companies competing to commercialise the next generation of orexin-targeting therapies. For Lilly, the acquisition extends a neuroscience portfolio that already spans Alzheimer's disease and immunology, adding a platform with read-through potential beyond sleep disorders into cognitive and neurodegenerative indications.

Market Intelligence

Market Implications

•Lilly's entry into orexin biology creates direct competitive pressure on Jazz Pharmaceuticals, which holds the incumbent narcolepsy franchise with Xyrem and Xywav. A well-capitalized Lilly commercial launch behind cleminorexton compresses Jazz's pricing power and patient retention in a disease with limited treatment alternatives. Jazz has no orexin-class asset in late-stage development, leaving it structurally exposed if cleminorexton achieves best-in-class wakefulness data.
•The Centessa deal is Lilly's second significant neuroscience or pipeline acquisition within days, following the Insilico AI licensing deal. Combined with Biogen acquiring Apellis and Merck acquiring Terns, this March represents a concentrated burst of large-cap pharma M&A across neuroscience and rare disease. Remaining standalone neuroscience platforms with Phase 2 or later orexin, cognitive, or sleep-wake assets now carry explicit takeout optionality that was not priced before this cluster.
•At $6.3bn upfront plus CVRs tied to FDA approvals through 2030, Lilly is allocating material capital to neuroscience at a moment when its balance sheet is simultaneously absorbing the GLP-1 competitive pricing war with Novo and elevated R&D spend. With Brent above $115 and macro headwinds compressing consumer discretionary, any delay to cleminorexton's FDA timeline or a GLP-1 volume miss would make this acquisition's CVR structure look like a capital misallocation under tightened financial conditions.

Connected Events

•Lilly's $2.75bn Insilico AI licensing deal announced two days prior shows Lilly is deploying capital across both platform technology and clinical-stage assets simultaneously, suggesting a deliberate acceleration of pipeline diversification beyond GLP-1 rather than opportunistic deal-making.here
•Biogen's $5.6bn all-cash Apellis acquisition and Merck's $6.7bn Terns deal, both announced within the same week, confirm that large-cap pharma M&A is clustering into a discrete window, likely driven by shared urgency around patent cliffs and the same set of available late-stage assets. Lilly's Centessa bid at $7.8bn is the largest of the three and raises the comp for remaining standalone neuroscience targets.here
•Novo Nordisk's discounted Wegovy subscription launch the same day as Lilly's Centessa announcement illustrates that Lilly's capital allocation is bifurcating: defending GLP-1 market share through pricing concessions while simultaneously building neuroscience through acquisitions. Both actions consume financial capacity concurrently, tightening Lilly's balance sheet flexibility.here

Also covering this story

New York Times CNBC PR Newswire

Eli Lilly acquires Centessa for up to $7.8bn to enter narcolepsy market

Lilly Bets $7.8bn on Orexin Biology to Build Sleep Medicine Franchise

Market Intelligence

Market Implications

Connected Events

Also covering this story

Related Stories

McCormick and Unilever's food division merge in $44.8bn deal

Biogen acquires Apellis Pharmaceuticals for $5.6bn cash

Sysco agrees $29bn acquisition of Jetro Restaurant Depot